Cigna updated IP0739 (effective 2026-03-01) to clarify coverage for GLP-1 and GLP-1/GIP agents used for weight management and related indications, emphasizing liraglutide (Saxenda/generic), Wegovy (injection and tablets), and Zepbound. The revision details FDA-approved indications, age and BMI thresholds, required behavioral interventions, time-limited initial authorizations, and criteria for continuation/maintenance (including response thresholds such as ≥5% weight loss). Wegovy dosing escalation, maintenance doses, and allowed switches between Wegovy injection and tablet formulations are specified, with timelines for safe transition and tolerability-based delays. MASH coverage requires documented F2–F3 fibrosis by accepted testing modalities and specific metabolic risk factors; concomitant use of multiple GLP-1 or GLP-1/GIP agents is explicitly considered not medically necessary across indications.
March 2026 Revision: Clarified Indications, Dosing, and Concomitant Use
Summary of changes in this revision
This revision of Cigna's IP0739 (effective 2026-03-01) consolidates and clarifies coverage criteria for GLP-1 receptor agonists and GLP-1/GIP receptor agonists used for weight management and related indications. The policy text emphasizes approved agents explicitly: liraglutide (Saxenda and generic), Wegovy (injection and tablet formulations), and Zepbound, including Zepbound's dual GLP-1/GIP activity. The document highlights FDA-indicated uses across adult and pediatric populations, CV risk reduction, MASH (formerly NASH), and moderate to severe obstructive sleep apnea.
The revision clarifies dosing escalation schedules and permitted switches between Wegovy injection and Wegovy tablet formulations, specifying timing for initiation after discontinuation of the alternative formulation (one week after stopping Wegovy 2.4 mg injection to start Wegovy 25 mg tablets; the day after stopping Wegovy 25 mg tablets to start Wegovy 2.4 mg injection). It also reaffirms that concomitant use of multiple GLP-1 or GLP-1/GIP agonists is considered not medically necessary.
Specified FDA-Approved Indications and Time-Limited Approvals
FDA-indicated uses and duration criteria for weight management and related conditions
The policy enumerates the FDA-approved indications for liraglutide, Wegovy (injection and tablet), and Zepbound for weight loss in adults and pediatric patients (≥12 years). For adult initial therapy, approvals are contingent on age (≥18), a trial of behavioral modification and dietary restriction (≥3 months), baseline BMI thresholds (≥35 kg/m2 or ≥27 kg/m2 with ≥2 specified comorbidities), and concurrent behavioral and reduced-calorie interventions. Approvals for initial therapy are specified for discrete durations (e.g., 4 months or 7 months in different sections of the document) depending on the listed criteria and agent.
The policy also includes FDA-approved indications beyond weight loss: risk reduction of major adverse cardiovascular events (MACE) with Wegovy in adults with established cardiovascular disease and overweight/obesity, treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with Wegovy tablet, and treatment of moderate to severe obstructive sleep apnea with Zepbound. For continuation/maintenance therapy, the policy specifies longer authorization windows (e.g., 1-year approvals for patients currently receiving certain therapies who meet response criteria such as ≥5% weight loss from baseline for adults on Wegovy injection or tablet).
Wegovy Dose Escalation, Maintenance Doses, and Formulation Switching
Detailed dosing, titration, and switching guidance included in coverage text
The policy reproduces recommended dosing escalation schedules from Wegovy prescribing information: a 16-week escalation to reach the 2.4 mg weekly injection (with the maintenance dose of 2.4 mg QW recommended for CV risk reduction and weight reduction and 1.7 mg QW as an alternative) and a 90-day escalation to reach 25 mg once-daily for Wegovy tablets. It notes the allowance to delay dose escalation by 4 weeks (injection) or to delay per tolerability (tablet) when intolerance occurs, and recommends considering re-escalation when tolerability permits. For the MASH indication, the 2.4 mg QW injection is the recommended maintenance dose with option to decrease to 1.7 mg QW if the higher dose is not tolerated.
Switching between formulations is specified: adults on Wegovy 2.4 mg injection may switch to Wegovy 25 mg tablets starting one week after discontinuing the injection; conversely, patients on Wegovy 25 mg tablets may start Wegovy 2.4 mg SC injection the day after stopping tablets. The policy also references consideration of switching to injection 1.7 mg QW for additional weight reduction in patients with type 2 diabetes who are on the 25 mg tablet.
MASH (NASH) Eligibility, Fibrosis Documentation, and Metabolic Risk Factors
Coverage criteria for MASH, fibrosis staging, and required documentation
For treatment of MASH (non-cirrhotic metabolic dysfunction-associated steatohepatitis) with moderate to advanced fibrosis, the policy requires stage F2 or F3 fibrosis prior to initiating Rezdiffra or Wegovy (documentation required). Acceptable documentation modalities listed include liver biopsy within 3 years, vibration-controlled transient elastography (VCTE) within 6 months, magnetic resonance elastography (MRE) within 6 months, or an Enhanced Liver Fibrosis (ELF) test within 6 months with a score between ≥ 9.2 to ≤ 10.5.
The policy specifies additional prescriber-reported metabolic risk factor requirements (e.g., central obesity, hypertriglyceridemia, reduced HDL-C, hypertension, and elevated fasting plasma glucose indicative of diabetes or pre-diabetes) and alcohol consumption thresholds for female patients (<20 grams/day) as part of the MASH-related criteria.
Conditions Not Covered: No Concomitant GLP-1 or GLP-1/GIP Use
Explicitly excluded uses: concomitant GLP-1/GLP-1-GIP therapy and other off-label combinations
The policy explicitly states that liraglutide (Saxenda/generic), Wegovy, and Zepbound are considered not medically necessary when used for other indications or concomitantly with other GLP-1 agonists or GLP-1/GIP agonists. The text reiterates that these agents should not be combined with each other or with other GLP-1 or GLP-1/GIP products, and lists examples of other GLP-1 agents (e.g., exenatide, Ozempic/semaglutide injection, Rybelsus/semaglutide tablets, Trulicity/dulaglutide, Victoza/liraglutide for diabetes) and a GLP-1/GIP example (Mounjaro/tirzepatide).
This exclusion applies across the covered indications and is highlighted as a standing condition not considered medically necessary, reflecting the policy's emphasis on single-agent GLP-1 or GLP-1/GIP use rather than combination therapy.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.